Alternative RUTFs for Treatment of Child Wasting

NCT ID: NCT06912620

Last Updated: 2025-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

2160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-21

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Acute malnutrition is the most life-threatening form of undernutrition. Moderate and severe acute malnutrition (MAM, SAM) are effectively treated with ready-to-use therapeutic foods (RUTFs) but there is a need to lower the cost of treatment and improve treatment regimens to reduce risk of relapse MAM/SAM episodes following recovery. The currently used standard formulation of RUTF contains peanuts and dairy, which pose problems due to their high cost, the need to import ingredients to the Global South (in the case of dairy), and risk of aflatoxin (in the case of peanuts). Before alternative formulations of RUTF can be recommended, however, there is the need for data on the efficacy of these formulations on recovery rates and to what extent recovery is sustainable. Sustainable recovery implies a lower rate of post-treatment relapse.

The study objectives are as follows: (1) To assess the non-inferiority of soy-maize-sorghum (SMS-) RUTF and soy-based (S-) RUTF on treatment recovery to standard RUTF; (2) To assess the superiority of SMS-RUTF and S- RUTF on post-recovery relapse compared to standard RUTF; (3) To assess the costs of a treatment course of SMS-RUTF, S-RUTF, and standard RUTF; (4) To assess the effect of SMS-RUTF and S-RUTF on microbiome composition and intestinal inflammation

The investigators will conduct a facility-based, individually randomized controlled trial with three arms allocated in a 1:1:1 allocation ratio in 30 health facilities (Centre de Santé et Promotion Sociale \[CSPS\]) in Burkina Faso. The investigators will randomize 1080 children with MAM and 1080 children with uncomplicated SAM 6-59 months of age to receive treatment with one of the following RUTFs: (1) standard of care, milk- and peanut-based RUTF (control group); (2) SMS-RUTF free of milk and peanuts and high in fiber (intervention 1); or (3) S-RUTF free of milk and peanuts (intervention 2). Children will be enrolled upon presentation to facilities for MAM or uncomplicated SAM treatment. Follow up visits will be weekly during treatment for SAM children and bi-weekly during treatment for MAM children, and monthly for 3 months following discharge from treatment. The primary study outcomes include, among others, anthropometric recovery at discharge (a non-inferiority analysis) and relapse to MAM or SAM within the 3 months following recovery (a superiority analysis). The investigators will employ an activity-based micro-costing approach to collect cost data on the direct and indirect medical costs, opportunity costs to caregivers, personnel, and overheads associated with outpatient MAM or SAM treatment. Fecal samples will be collected from children at a subset of facilities (5 facilities, \~60 children per treatment arm), at enrollment (initiation of treatment), discharge from treatment, and 3-months post-discharge.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Acute Malnutrition Moderate Acute Malnutrition Wasting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
The products will be provided in identical packaging and the participants, the care providers, the investigators, and outcomes assessors will be blinded to treatment assessment. However, the products may taste different and thus participants may know that they are receiving an alternative RUTF if they are familiar with the standard RUTF product.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard RUTF

This is the control arm of the trial, in which children will receive the standard RUTF product for treatment of acute malnutrition

Group Type ACTIVE_COMPARATOR

Standard RUTF

Intervention Type DIETARY_SUPPLEMENT

This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients

Soy-based RUTF

This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-based RUTF

Group Type EXPERIMENTAL

Soy-based RUTF

Intervention Type DIETARY_SUPPLEMENT

This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids

Soy-maize-sorghum-based RUTF

This is an interventional arm of the trial, in which children will receive an alternative formulation, a soy-maize-sorghum-based RUTF

Group Type EXPERIMENTAL

Soy-maize-sorghum-based RUTF

Intervention Type DIETARY_SUPPLEMENT

This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soy-based RUTF

This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free formula that includes dairy (milk powder) with added crystalline amino acids

Intervention Type DIETARY_SUPPLEMENT

Soy-maize-sorghum-based RUTF

This alternative formulation of ready-to-use therapeutic foods (RUTFs) is a peanut-free and dairy-free formula with added crystalline amino acids

Intervention Type DIETARY_SUPPLEMENT

Standard RUTF

This is the control, the standard, currently used formulation of ready-to-use therapeutic foods (RUTFs), which contains dairy and peanut ingredients

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 6-59 months
* MUAC \< 12.5 cm, or WLZ/WHZ \< -2
* Absence of clinical complications or nutritional edema
* Pass the appetite test
* Accompanied by caregiver or legal guardian
* Caregiver or legal guardian consents to participate

Exclusion Criteria

* Acute malnutrition requiring hospitalization (presence of clinical complications, failure to pass the appetite test, or presence of bilateral pitting edema)
* Known allergy to any of the ingredients in the RUTF products
* Already enrolled in MAM or SAM treatment program
* Presence of physical abnormalities that make measurement of anthropometry impossible
* Caregiver has intention to move out of the study area within the next 6 months
* Children referred from in-patient facilities to continue in ambulatory care
Minimum Eligible Age

6 Months

Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AFRICSante

UNKNOWN

Sponsor Role collaborator

Institut de Recherche en Sciences de la Sante, Burkina Faso

OTHER_GOV

Sponsor Role collaborator

International Food Policy Research Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Laeticia Toe

Role: PRINCIPAL_INVESTIGATOR

Institut de Recherche en Sciences de la Santé

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Health centers localted in the region of Hauts-Bassins

Bobo-Dioulasso, , Burkina Faso

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Burkina Faso

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rebecca Brander

Role: CONTACT

+1 (202) 862-5600

Lieven Huybregts

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alain Hien, MSc, PhD

Role: primary

70 96 07 25 ext. +226

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2024-RUTF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.